Latest Breaking News On - சாரா எல்டன் ஃபார் - Page 1 : comparemela.com

Medicago and GSK Announce Positive Interim Phase 2 Results for Adjuvanted COVID-19 Vaccine Candidate Neutralizing antibody responses were 10 times higher than people recovering from COVID-19 No related severe adverse events reported Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) are pleased to report positive interim Phase 2 clinical trial safety and immunogenicity data for Medicago s plant-derived COVID-19 vaccine candidate, which has been tested in combination with GSK s pandemic adjuvant. These results are part of the ongoing Phase 2/3 study and reiterate the promising profile observed during Phase 1 testing. Immunogenicity, as measured by the neutralizing antibody titer, was high about 10 times higher than those in a panel of sera from patients recovering from COVID-19. No related severe adverse events were reported and reactogenicity was generally mild to moderate and short in duration.

United statesUnited kingdomCity ofSimon mooreSarah elton farrKathleen quinnThomas breuerJeff mclaughlinSimon steelNathalie landryJames dodwellAffairs at medicagoHealth canadaQuebec cityExecutive vice presidentMedical affairs